1 129

Cited 0 times in

췌장암의 2차 항암치료

Other Titles
 Second Line Chemotherapy for Pancreatic Cancer 
Authors
 박정엽 
Citation
 Korean Journal of Gastroenterology, Vol.57(4) : 207-212, 2011 
Journal Title
 Korean Journal of Gastroenterology 
ISSN
 1598-9992 
Issue Date
2011
Abstract
Pancreatic cancer is a very lethal cancer. It is the 5th most common cause for cancer related mortality in Korea. Most of patients have unresectable pancreatic cancer, and systemic chemotherapy remains the only treatment option for them. Gemcitabine has been adopted as the standard first-line agent for advanced pancreatic cancer, but the progression free survival with gemcitabine is short. Many of patients need further treatment. We reviewed the clinical trials of second line chemotherapy for gemcitabine refractory pancreatic cancer and tried to show currently available treatment options
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/93037
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
박정엽(Park, Jeong Youp)
사서에게 알리기
  feedback
Full Text
http://kiss.kstudy.com/journal/thesis_name.asp?tname=kiss2002&key=2904944
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse